ozempic semaglutide patent expiry Growing concerns over weight loss drugs as patents set to expire What's next for Ozempic after

The upper arm falls somewhere in between but is harder to self-inject without assistance

You may be a candidate for GLP-1 medication if you have a BMI in the overweight or obese range, or if you have a condition called insulin resistance

So far, clinical trials suggest that people taking retatrutide may experience greater overall weight loss than what has been seen with earlier GLP-1 medications

However, its dosing requires precision and individualization, highlighting the key difference between the 2.5mg and 5mg strengths

At 6 months, 68% had returned to weekly dosing, citing no perceived benefit and increased hassle

Number of patients on GLP-1, whether for diabetes or obesity, has tripled in the last three years thanks to Novo Nordisk and Eli Lilly